24/7 Market News Snapshot 22 October, 2024 – Nexalin Technology, Inc. Common Stock (NASDAQ:NXL)

October 22, 2024

DENVER, Colo., 22 October, 2024 (247marketnews.com) – (NASDAQ:NXL) are discussed in this article.
Nexalin Technology, Inc. (NXL) has emerged as a notable player in the market, opening at $1.52 and currently trading at approximately $1.794, reflecting a significant increase of 21.22%. This positive momentum follows a previous close of $1.480, drawing keen interest from investors, especially with a trading volume surpassing 1.03 million shares. The market’s enthusiastic reception is indicative of NXL’s promising growth trajectory.

Simultaneously, Nexalin has announced an innovative clinical trial in partnership with a prestigious academic institution, focusing on the treatment of veterans suffering from mild Traumatic Brain Injury (mTBI). This groundbreaking study aims to transform the treatment landscape using Nexalin’s advanced Gen-3 Halo headset, designed for at-home applications within a virtual clinic model.

Under the leadership of Dr. Ming Xiong Huang, the study will recruit veterans diagnosed with Traumatic Brain Injury and utilize Nexalin’s proprietary Deep Intracranial Frequency Stimulation (DIFS®) technology. The approach facilitates high-quality neurostimulation treatments in a comfortable home environment, addressing traditional barriers associated with hospital visits.

This clinical trial builds on previous encouraging results from a study using Nexalin’s Gen-2 console device, which demonstrated significant improvements in brain activity and pain relief. The new investigation, titled “MEG Study of the Transcranial Electrical Stimulation Treatment for Mild Traumatic Brain Injury using the Nexalin Halo Headset,” will assess brain activity and symptom relief in both a treatment group and a control group using a sham device. This dual-group design aims to connect neuroimaging results with improvements reported by patients.

Aligning with the Veterans Administration’s goal of expanding therapeutic telehealth services, Nexalin’s initiative underscores its commitment to advancing veterans’ mental health care. Mark White, CEO of Nexalin Technology, expressed optimism about the integration of their innovative solutions, highlighting the importance of accessible and non-invasive treatments for those in need.

Related news for (NXL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.